← Back to all signals
RESEARCH PAPER ANALYSIS

Metric validation for detection of delayed and directed coupling.

This methods study benchmarks common effective connectivity metrics on simulated time-delayed networks and finds multivariate transfer entropy most accurate but computationally intensive, while zero-lag metrics fail for time-lagged interactions and simpler metrics (Granger causality, mutual…

PMID41985540
JournalJournal of neural engineering
Publication Date2026-04-15
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

This methods study benchmarks common effective connectivity metrics on simulated time-delayed networks and finds multivariate transfer entropy most accurate but computationally intensive, while zero-lag metrics fail for time-lagged interactions and simpler metrics (Granger causality, mutual…

WHY IT MATTERS

Research significance

Reliable EC metric selection for noisy, sparsely sampled human electrophysiology improves reconstruction of directed brain networks, which is a necessary step toward robust electrophysiology-based biomarkers and circuit-targeted therapies (e.g., DBS optimization) in Parkinson's disease.

ABSTRACT

Source abstract

The brain functions as a complex network of billions of interconnected neurons, coordinating processes from basic reflexes to high-level cognition. Dysfunction in these networks contribute to neurological and psychiatric disorders, including epilepsy, depression, and Parkinson's disease. Understanding these network alterations is essential for developing effective therapies. However, reconstructing network topology from human electrophysiology data is challenging due to sparse spatial sampling, measurement noise, and variable time delays in interregional communication. Effective connectivity (EC) metrics have been developed to infer directed neural interactions, but their accuracy under real-world data constraints remain unclear. This study empirically compares the ability of common EC metrics to reconstruct relationships between simulated time series with known temporal relationships and network topologies in the presence of data limitations common to human electrophysiology data. By utilizing networks and temporal relationships that are mathematically simple, this framework provides broad conceptual backing to understand the reliability of EC metrics and establishes groundwork upon which more complex spatial and temporal relationships between time series can be evaluated.&#xD;Approach: We generated Erdős-Rényi networks and simulated time series using a time-delayed vector autoregressive (VAR) model. We systematically varied network size, data length, measurement noise, and network coverage. Variations of four commonly used EC metrics, cross-correlation, Granger causality, mutual information, and transfer entropy, were evaluated for reconstruction accuracy using cosine distance, as well as receiver operating characteristic (ROC) curves, to compare estimated and true coupling matrices. &#xD;Main Results: Multivariate transfer entropy demonstrated the highest accuracy across various conditions but required significantly longer computation times. For small networks (<30 nodes), mutual information and Granger causality rapidly and accurately reconstructed networks. For larger networks, partial cross-correlation performed well with good computational efficiency. Notably, zero-lag metrics perform no better than chance for time-lagged time series relationships in nearly all conditions.&#xD;Significance: The choice of an EC metric should consider specific data constraints. While multivariate transfer entropy is the most reliable across conditions, its long runtime limits its practical application. For large networks, partial cross-correlation offers a faster and reasonably accurate alternative. Granger causality and mutual information are effective for small networks. Critically, time-lagged metrics are essential for accurate network reconstructions, as failing to account for time delays leads to reconstructions no more accurate than random network models.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic